Guideline for Selecting Basal Insulin: Glargine vs. Degludec

First‑Line Recommendation

• For most adults with type 1 or type 2 diabetes who need basal insulin, initiate insulin glargine U‑100 as the first‑line basal insulin because of its lower acquisition cost, well‑established safety profile, and glycemic efficacy equivalent to insulin degludec [1][2].

Glycemic Efficacy

• Glargine U‑300 provides a longer duration of action than glargine U‑100 but has modestly lower per‑unit efficacy, requiring a slightly higher total daily dose to achieve the same fasting glucose target [1][2].

Hypoglycemia Considerations

• In elderly patients (≥ 65 years) with hypoglycemia unawareness, degludec’s modest reduction in nocturnal hypoglycemia offers a clinically meaningful benefit and should be prioritized [1][2].

Age‑Specific Dosing

• Initiate basal insulin in older adults at low doses (0.1–0.25 U/kg/day) for either glargine or degludec to reduce the risk of hypoglycemia [1][2].

Renal Impairment Adjustments

• For patients with end‑stage renal disease (CKD stage 5), reduce the total daily basal insulin dose by 50 % in type 2 diabetes and by 35–40 % in type 1 diabetes, irrespective of whether glargine or degludec is used [1][2].
• In individuals with eGFR < 45 mL/min/1.73 m², titrate conservatively because both agents have prolonged action in renal impairment [1][2].

Formulations & Delivery Devices

• Glargine U‑100 is offered both in vials and prefilled pens, providing flexibility for dose adjustments [1][2].
• Glargine U‑300 (Toujeo) is available only in prefilled pens, delivers three‑fold concentration, and reduces injection volume for patients requiring high basal doses (> 40 U) [1][2].
• Degludec U‑200 and glargine U‑300 are supplied exclusively in prefilled pens to minimize dosing errors; they should never be drawn into standard syringes [1][2].

Cost & Value

• Glargine U‑100 (generic/biosimilar) costs approximately $95–$136 per 1,000 U (NADAC/AWP), making it the most affordable basal insulin [1][2].
• Degludec U‑100 costs roughly $114–$142 per 1,000 U, representing a modest premium over generic glargine [1][2].
• Degludec U‑200 costs about $85–$113 per 1,000 U, providing cost savings for patients who need high basal doses (> 60 U/day) [1][2].
• Glargine U‑300 is the most expensive basal formulation at $290–$363 per 1,000 U [1][2].

Practical Initiation & Titration (Type 2 Diabetes)

• Start glargine U‑100 or degludec at 10 U once daily (or 0.1–0.2 U/kg/day) in insulin‑naïve patients [1][2].
• Titrate by 2 U every 3 days if fasting glucose is 140–179 mg/dL; increase by 4 U every 3 days if fasting glucose ≥ 180 mg/dL [1][2].
• Aim for a fasting glucose target of 80–130 mg/dL [1][2].
• When basal insulin reaches ≈ 0.5 U/kg/day without achieving A1C goals, add prandial insulin or a GLP‑1 receptor agonist rather than further escalating basal dose [1][2].

Switching Between Formulations

• Transitioning from glargine U‑100 to glargine U‑300 typically requires a 10–20 % increase in total daily dose because of the modestly lower per‑unit efficacy of the concentrated formulation [1][2].

Common Pitfalls & Mitigation

• Both glargine and degludec need dose reductions in renal impairment; failure to adjust can precipitate hypoglycemia [1][2].
• Concentrated insulins (degludec U‑200, glargine U‑300) should only be administered using their dedicated prefilled pens to avoid dosing errors [1][2].

Ultra‑Long‑Acting Basal Insulin Degludec – Clinical Profile and Economic Considerations

Classification and Pharmacologic Characteristics

• Insulin degludec is an ultra‑long‑acting basal insulin analog with a duration of action exceeding 42 hours, providing flat and stable glucose‑lowering effects for more than 24 hours, as described by the American Diabetes Association. 3, 4
• The American Diabetes Association classifies degludec among “new longer‑acting basal analogs” together with insulin glargine U‑300, distinguishing these from earlier basal analogs (U‑100 glargine, detemir) and intermediate‑acting insulins (NPH). 3, 4
• Degludec is marketed in two concentrations: a U‑100 formulation in cartridges and a U‑200 formulation in prefilled pens; the U‑200 version has pharmacokinetics comparable to the U‑100 but permits higher dose delivery per injection volume. 5

Hypoglycemia Risk

• In individuals with type 1 diabetes, degludec reduces nocturnal confirmed hypoglycemia by approximately 25 % compared with insulin glargine U‑100 in randomized clinical trials. 3

Economic and Safety Considerations

• Cost‑effectiveness analyses indicate that using degludec as basal‑only therapy costs roughly $406,000 per quality‑adjusted life‑year gained relative to glargine, reflecting limited value for most patients. 6, 7
• The U‑200 formulation of degludec is available only in prefilled pens to minimize dosing errors; when a vial is prescribed, a specific high‑concentration syringe (e.g., U‑500) is required to avoid medication errors. 5

Comparison of Tresiba and Lantus for Diabetes Management

Glycemic Control and Hypoglycemia Risk

• The American Diabetes Association guidelines acknowledge that newer long-acting basal analogs like degludec may confer lower hypoglycemia risk compared to U-100 glargine in patients with type 1 diabetes, with a moderate level of evidence 8

Pharmacokinetic Differences and Clinical Benefits

• Glargine has an onset of approximately 1 hour with a relatively peakless profile lasting up to 24 hours, whereas degludec has an ultra-long duration of action exceeding 42 hours, according to the American Association of Clinical Endocrinologists 9

Dosing Flexibility and Cardiovascular Safety

• The American Diabetes Association emphasizes that glargine should be administered at a consistent time each day to maintain stable blood glucose levels, in contrast to degludec which can be administered at varying times of day without loss of efficacy, with a high level of evidence 10

Treatment Guidelines and Recommendations

• The ADA/EASD consensus recommends GLP-1 receptor agonists as the preferred injectable medication before insulin for most patients with type 2 diabetes, though basal insulin remains appropriate when extreme hyperglycemia is present, with a strong level of evidence 11
• When basal insulin exceeds 0.5 units/kg/day with A1C still above target, consider adding GLP-1 receptor agonists or prandial insulin rather than continuing to escalate basal insulin alone, according to the American Diabetes Association, with a moderate level of evidence 11